QuBEST BIO

QuBEST BIO is a nonclinical and preclinical CRO that has provided experienced and high performance services to the South Korean biotech industry since 2008 and is now also opening its services to the global market. Bioanalysis Capabilities: - Rapid Discovery Screen – Rapid Screening for Hit-to-Lead - Lead Optimization (Non-GLP Early PK Studies) – PK for Candidate Selection - Lead Qualification (Non-GLP TK Studies) – Systemic Exposure from DRF - Method Development, Validation and Sample Analysis (various matices) - Small molecules + metabolites, peptides, ADC free payload, etc. - GLP Bioanalysis (by 3Q 2025) In Vivo Pharmacokinetic Studies (non-radiolabeled): - Species: all laboratory species including NHPs - Bioequivalence / Bioavailability assessments - Gender difference / Food effects - Parameter calculation using R packages for noncompartmental analysis - Dose, bleed & ship - Excel data sheet / full report Facilities and Instrumentation: - Dedicated laboratory spaces – PK animal room - 8 Triple Quadrupole Mass Spectrometers – AB Sciex 6500+ (2), 5500+ (3), and 4500 (3) w/ UHPLC systems Extensive Bioanalysis Experience for Popular API: Semaglutide, Rivastigmine, Donepezil, Leuprolide, Dexamethasone, Entecavir, Finasteride, Ropivacaine, Exenatide, Tirzepatide, Nicotinamide adenine dinucleotide(NAD), Pamoic acid, Phenacetin, Tolbutamide, Bupropion, Amodiaquine, S-Mephenytoin, Dextromethorphan, Midazolam, Metformin, Furosemide, Niclosamide, Testosterone, Goserelin, Dutasteride, Diclofenac, Clozapine, Desipramin As part of a rapidly-expanding and highly-specialized South Korean biotech industry, we believe in doing our work with the utmost efficiency at the highest standard while also providing cost-effective services. And as a team with high levels of knowledge, experience, skills, project management know-how, networking, collaborative efforts, and most of all, passion, let us show you how we can help reach your drug development pipeline goals.